![Karolinska Developme](/news-release/logo/284751/0/284751.gif?lastModified=12%2F09%2F2016%2022%3A42%3A17&size=2)
Karolinska Development portfolio company Promimic AB appoints Magnus Larsson as new CEO and launches US sales operation
January 18, 2017 02:00 ET
|
Karolinska Development AB
Details from the Promimic announcement follow:
Magnus Larsson has a solid background in Sales and Marketing, having held a number of leadership positions in the international dental...
![Aprea Therapeutics A](/news-release/logo/284751/0/284751.gif?lastModified=12%2F09%2F2016%2022%3A42%3A17&size=2)
Aprea Therapeutics Announces Presentation at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco
January 05, 2017 02:00 ET
|
Karolinska Development AB
About Aprea Therapeutics AB
Aprea Therapeutics AB is a Boston, Massachusetts- and Stockholm, Sweden-based biopharmaceutical company focused on the discovery and development of novel anticancer...
![Karolinska Developme](/news-release/logo/284751/0/284751.gif?lastModified=12%2F09%2F2016%2022%3A42%3A17&size=2)
Karolinska Development portfolio company Dilafor initiates Phase IIb clinical trial with tafoxiparin in women with protracted labor
January 04, 2017 02:00 ET
|
Karolinska Development AB
Details from the Dilafor press release follow:
Tafoxiparin is in clinical development as a new treatment designed to decrease the incidence of protracted labor (i.e labor that lasts more...
![Karolinska Developme](/news-release/logo/284751/0/284751.gif?lastModified=12%2F09%2F2016%2022%3A42%3A17&size=2)
Karolinska Development portfolio company Dilafor AB granted U.S. patent for Phase II drug tafoxiparin
December 02, 2016 02:00 ET
|
Karolinska Development AB
Details from the Dilafor press release follow:
Tafoxiparin is in clinical development as a new treatment designed to decrease the incidence of protracted labor both after induction of...
![Karolinska Developme](/news-release/logo/284751/0/284751.gif?lastModified=12%2F09%2F2016%2022%3A42%3A17&size=2)
Karolinska Development company Modus Therapeutics to present poster at 58th ASH Annual Meeting in San Diego
December 01, 2016 02:00 ET
|
Karolinska Development AB
Details from the Modus Therapeutics press release follow:
The poster entitled: Sevuparin Blocks Sickle Blood Cell Adhesion and Sickle-Leukocyte Rolling on Immobilized L-Selectin in a Dose...
![Karolinska Developme](/news-release/logo/284751/0/284751.gif?lastModified=12%2F09%2F2016%2022%3A42%3A17&size=2)
Karolinska Development: Interim Report for January-September 2016
November 23, 2016 01:50 ET
|
Karolinska Development AB
Jim Van heusden, CEO, comments: “During the third quarter 2016, Karolinska Development saw several of its portfolio companies secure new funds to finance the progression of their businesses toward...
![Karolinska Developme](/news-release/logo/284751/0/284751.gif?lastModified=12%2F09%2F2016%2022%3A42%3A17&size=2)
Karolinska Development: Delårsrapport för januari - september 2016
November 23, 2016 01:50 ET
|
Karolinska Development AB
Jim Van heusden, CEO, kommenterar: “Under tredje kvartalet 2016 har flera av Karolinska Developments portföljbolag säkrat ny finansiering för att utveckla verksamheten mot sina definierade...
![Karolinska Developme](/news-release/logo/284751/0/284751.gif?lastModified=12%2F09%2F2016%2022%3A42%3A17&size=2)
Karolinska Development company Umecrine Cognition raises SEK 45 million to advance GR3027, a novel drug candidate for hepatic encephalopathy
November 22, 2016 02:00 ET
|
Karolinska Development AB
Details from the Umecrine Cognition press release follow:
Hepatic encephalopathy (HE) is a serious brain disorder and one of the primary complications in acute and chronic liver disease....
![Karolinska Developme](/news-release/logo/284751/0/284751.gif?lastModified=12%2F09%2F2016%2022%3A42%3A17&size=2)
Karolinska Development – Delårsrapport för januari - september 2016, inbjudan till telefonkonferens och webbpresentation
November 17, 2016 02:19 ET
|
Karolinska Development AB
Vänligen ring in på något av följande telefonnummer några minuter före telefonkonferensens start:
Från Sverige: +46 (0) 8 505 564 74
Från USA: +1 855 753 22 30
Från Storbritannien: +44...
![Karolinska Developme](/news-release/logo/284751/0/284751.gif?lastModified=12%2F09%2F2016%2022%3A42%3A17&size=2)
Karolinska Development – Q3 2016 Interim Report - invitation to conference call and webcast
November 17, 2016 02:00 ET
|
Karolinska Development AB
Please dial in at one of the following numbers a few minutes before the start of the conference call:
From Sweden: +46 (0) 8 505 564 74
From the US: +1 855 753 22...